Clovis Oncology (NASDAQ:CLVS) Receiving Positive News Coverage, Analysis Finds

Headlines about Clovis Oncology (NASDAQ:CLVS) have trended positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Clovis Oncology earned a news sentiment score of 0.33 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 93 out of 100, meaning that recent press coverage is extremely likely to have an impact on the stock’s share price in the near future.

These are some of the news stories that may have effected Accern’s scoring:

A number of research firms recently issued reports on CLVS. Piper Jaffray Companies set a $77.00 price objective on Clovis Oncology and gave the company a “buy” rating in a report on Tuesday, March 14th. J P Morgan Chase & Co restated a “hold” rating on shares of Clovis Oncology in a report on Wednesday, March 15th. Goldman Sachs Group, Inc. (The) boosted their price objective on Clovis Oncology from $44.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, March 15th. Chardan Capital reaffirmed a “sell” rating and set a $36.00 target price on shares of Clovis Oncology in a research report on Thursday, March 16th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $74.00 target price on shares of Clovis Oncology in a research report on Tuesday, April 18th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $75.69.

Clovis Oncology (NASDAQ:CLVS) traded up 0.81% on Wednesday, hitting $94.85. The stock had a trading volume of 81,520 shares. The company’s market cap is $4.25 billion. Clovis Oncology has a 52-week low of $13.43 and a 52-week high of $96.92. The firm’s 50-day moving average is $64.85 and its 200-day moving average is $58.78.

Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.43) by $0.10. The company had revenue of $7.05 million during the quarter, compared to analysts’ expectations of $6.04 million. Equities research analysts anticipate that Clovis Oncology will post ($5.78) earnings per share for the current fiscal year.

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $61.82, for a total value of $185,460.00. Following the completion of the transaction, the insider now directly owns 200,583 shares in the company, valued at $12,400,041.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders sold 9,000 shares of company stock valued at $495,690. 17.40% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Clovis Oncology (NASDAQ:CLVS) Receiving Positive News Coverage, Analysis Finds” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/07/12/clovis-oncology-nasdaqclvs-receiving-positive-news-coverage-analysis-finds.html.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply